SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Agios Pharmaceuticals logo
4 weeks ago

Associate Director, Field Marketer, Southwest

Agios Pharmaceuticals

USA (Remote)Full time$154K/yr – $230K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Agios Pharmaceuticals logo

Associate Director, Field Marketer, Southwest

Agios Pharmaceuticals

USA (Remote)

$154K/yr - $230K/yrIn-houseFull-timeSenior level7+ years exp.
4 weeks ago
Agios Pharmaceuticals logo
Agios Pharmaceuticals

Associate Director, Field Marketer, Southwest

USA (Remote)

$154K/yr – $230K/yrSenior Level7+ years expFull time

Posted 4 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and coordinate KOL relationships and insights to shape the market and product strategy across US and Global horizons, with executive encounters and cross-functional engagement as core levers.

  • KOL ecosystem ownership: identify, engage, and manage thought leaders for advisory, boards, and speaking engagements.

Job Description

Responsibilities

  • Cultivate and maintain relationships with KOLs in our industry
  • Gather insights from KOLs about market and product to inform marketing strategy and tactics
  • Collaborate closely with cross-functional partners on KOL approach and engagement
  • Support identification of and serve as the liaison with KOLs for approved commercial efforts (Ad boards, Speakers Bureau, Ad Hoc consulting, etc.)
  • Participate (and set up executive encounters as required) in US and Global Congress activities
  • Provide regular updates to management and cross-functional teammates of KOL management progress and insights

Requirements

  • Bachelor’s degree in business, science, engineering, or related field
  • Minimum of 7 years of field sales, field marketing or Thought Leader Liaison experience, with field marketing/ Thought Leader Liaison experience preferred
  • Rare Disease experience required. Hematology/Oncology experience preferred.
  • Documented track record of delivering consistent, exceptional levels of performance and leadership
  • Highly motivated, entrepreneurial, self-starter, with experience effectively partnering with HCPs
  • Demonstrated ability to manage a large geography
  • Demonstrated strong strategic thinking and an ability to work collaboratively and effectively with a wide range of people and functions
  • Strong interpersonal skills, with ability to establish a rapport quickly with others
  • Excellent communication and influencing skills
  • Ability to manage multiple and changing priorities in a fast-paced environment

Preferred

  • Hematology/Oncology experience preferred.

Benefits

  • Deliberate Development. Your professional growth as one of our top priorities.
  • Flexibility. We’re all about individual needs. We embrace different perspectives, work styles, health and wellness approaches, care of families and productivity.
  • Premium benefits package. We invest in the health, wellbeing, and security of our people with a premium benefits package that is well-rounded and flexible to help meet the varied personal and professional needs of every member of our team.
  • Psychological safety. We support an environment of fearlessness. We want you to share your ideas, speak candidly and take data-informed risks to help push the boundaries.
  • Commitment to diversity. We strive to foster a welcoming workplace where everyone can thrive. We’re continuously looking to improve the inclusivity of our workforce.
  • Commitment to community. We’re an active participant in the communities that surround us – the communities where we live, and the community of people and their loved ones in need of better treatment options for conditions that are often overlooked.
Agios Pharmaceuticals logo

Agios Pharmaceuticals

4.0 Glassdoor

Agios is a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with rare disease communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. Rooted in hematology, we combine deep biological expertise with real-world insights to advance a growing pipeline of medicines that reflect the priorities of rare disease communities.Our inclusive, collaborative culture sparks bold thinking and strengthens our connections – with each other and with the people we serve.Review our social media guidelines: https://www.agios.com/community-guidelines/

Founded in 2008
Cambridge, Massachusetts, USA
675 employees (26 in marketing)
www.agios.com
81% recommend to a friend
81% CEO approval

Traffic Signals

Monthly Visitors
21.8K
Traffic Source Mix
Search
47%
Direct
41.4%
Referral
7.1%
Social
2.3%
Paid
1.9%

Headcount Trend

Current headcount: ~676

Marketing Team

Marketing Team Size
26 (4% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$775.8M
Last Raise
$256M
Post IPO Equity, 6 years ago

Funding History

  • Nov 2019
    Post IPO Equity • $256M
  • Jan 2018
    Post IPO Equity • $400M
  • Sep 2016
    Post IPO Equity

Recent News

Recon: FDA misses PDUFA goal date for Agios' thalassemia therapy; Mirum to buy Bluejay for up to $820M
Dec 8, 2025 • Regulatory Affairs Professionals Society | RAPS
Agios still waiting for FDA decision on Pyrukynd thalassemia filing
Dec 8, 2025 • FirstWord Pharma
FDA delays decision on Agios’ thalassemia drug application
Dec 8, 2025 • Investing.com
Agios Pharmaceuticals Provides Update on FDA Review Status for Supplemental New Drug Application of Mitapivat for Thalassemia
Dec 8, 2025 • Quiver Quantitative
Agios Faces A Make-Or-Break Year As Key Drug Decisions Loom
Dec 7, 2025 • Finimize
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals
Dec 6, 2025 • Yahoo Finance
Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat
Dec 4, 2025 • Sahm
Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat
Dec 3, 2025 • simplywall.st
A Look at Agios Pharmaceuticals (AGIO) Valuation Following Strong Phase 3 Sickle Cell Trial Results
Nov 29, 2025 • simplywall.st
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst
Nov 25, 2025 • Yahoo Finance
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug
Nov 20, 2025 • MSN
Agios Pharma stock price target lowered to $48 at H.C. Wainwright on mixed trial data
Nov 20, 2025 • Investing.com
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story
Nov 20, 2025 • Yahoo Finance
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug
Nov 20, 2025 • Stocktwits
A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%.
Nov 19, 2025 • MSN
Agios Pharmaceuticals (AGIO) Shares Plummet by Over 47%
Nov 19, 2025 • GuruFocus
Agios readies FDA push in sickle cell disease despite mixed ph. 3 results, shares plummet
Nov 19, 2025 • Fierce Pharma
Agios reports mixed results from sickle cell study, raising doubts about drug’s future
Nov 19, 2025 • statnews.com
Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility (AGIO)
Nov 19, 2025 • Seeking Alpha
Agios planning sNDA on mixed sickle cell data for mitapivat
Nov 19, 2025 • BioWorld MedTech
Why Shares in Agios Pharmaceuticals Got Crushed Today
Nov 19, 2025 • The Motley Fool
Agios Pharmaceuticals stock tumbles after mixed sickle cell trial results
Nov 19, 2025 • Investing.com
Agios hit as mitapivat delivers mixed data in pivotal sickle cell study
Nov 19, 2025 • FirstWord Pharma
Agios (Nasdaq: AGIO) Shares Phase 3 Mitapivat Sickle Cell Data, Eyes 2026 U.S. Filing
Nov 19, 2025 • Stock Titan
Agios Pharmaceuticals (AGIO) Shares Plummet After Mixed Trial Re
Nov 19, 2025 • GuruFocus
A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%.
Nov 19, 2025 • Barron's
Agios Pharmaceuticals (AGIO): Assessing Current Valuation After Strong Revenue Growth and Improved Net Income
Nov 19, 2025 • Yahoo Finance
Agios Pharmaceuticals Reports Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease, Meeting Primary Endpoint of Hemoglobin Response
Nov 19, 2025 • Quiver Quantitative
Agios shares fall on mixed sickle cell results for blood disease drug
Nov 19, 2025 • BioPharma Dive
A preview of Agios Pharma’s sickle-cell study readout
Nov 13, 2025 • statnews.com
Agios Pharmaceuticals Shows Rising Price Performance With Jump To 84 RS Rating
Nov 12, 2025 • Investor's Business Daily
Could Mitapivat Data Shift Agios Pharmaceuticals’ (AGIO) Competitive Edge in Rare Blood Disorders?
Nov 9, 2025 • simplywall.st
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidate - Weekly Investment Recap & Reliable Breakout Forecasts
Nov 7, 2025 • newser.com
Is it time to cut losses on Agios Pharmaceuticals Inc. - Trade Signal Summary & Daily Profit Maximizing Tips
Nov 7, 2025 • newser.com
Is Agios Pharmaceuticals Inc. building a consolidation base - Quarterly Earnings Summary & Intraday High Probability Setup Alerts
Nov 7, 2025 • newser.com
What earnings revisions data tells us about Agios Pharmaceuticals Inc. - 2025 Buyback Activity & Daily Growth Stock Tips
Nov 6, 2025 • newser.com
What data driven models say about Agios Pharmaceuticals Inc.’s future - 2025 Growth vs Value & Reliable Breakout Forecasts
Nov 6, 2025 • newser.com
Agios Pharmaceuticals (AGIO): Assessing Valuation After Mitapivat’s New Data Brings Pipeline Back Into Focus
Nov 6, 2025 • simplywall.st
What earnings revisions data tells us about Agios Pharmaceuticals Inc. - Portfolio Update Summary & Smart Investment Allocation Insights
Nov 6, 2025 • newser.com
What earnings revisions data tells us about Agios Pharmaceuticals Inc. - July 2025 Intraday Action & Weekly Chart Analysis and Trade Guides
Nov 6, 2025 • newser.com
Agios Pharmaceuticals Sees Relative Strength Rating Improve To 74
Nov 5, 2025 • Investor's Business Daily
Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones
Nov 4, 2025 • Seeking Alpha
Agios Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating
Nov 3, 2025 • Investor's Business Daily
How Investors May Respond To Agios Pharmaceuticals (AGIO) Pipeline Progress and Narrowed Third-Quarter Losses
Nov 1, 2025 • simplywall.st
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2025 Earnings Call Transcript
Nov 1, 2025 • Insider Monkey
Agios Pharmaceuticals’ Earnings Call: Growth and Challenges
Nov 1, 2025 • TipRanks
Agios Pharmaceuticals (AGIO) Posts $1.1 Billion One-Off Gain, Challenges Earnings Quality Narratives
Oct 31, 2025 • simplywall.st
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Oct 31, 2025 • Yahoo Finance
Agios Pharmaceuticals (AGIO) Posts $1.1 Billion One-Off Gain, Challenges Earnings Quality Narratives
Oct 31, 2025 • Sahm
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi
Oct 31, 2025 • GuruFocus
Agios Pharmaceuticals: Q3 Earnings Snapshot
Oct 31, 2025 • Greenwich Time
Agios Pharmaceuticals’ AG-236 Study: A Potential Game-Changer in Drug Development
Oct 30, 2025 • MSN
Agios Pharmaceuticals Inc (AGIO) Q3 2025 Earnings: EPS of -$1.78
Oct 30, 2025 • GuruFocus
Agios Pharmaceuticals: Q3 Earnings Snapshot
Oct 30, 2025 • San Francisco Chronicle
Agios Pharmaceuticals Reports $12.9 Million in Q3 PYRUKYND Revenues and Updates on Key Clinical Milestones
Oct 30, 2025 • Quiver Quantitative
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report
Oct 30, 2025 • TradingView
Agios Pharmaceuticals Inc (AGIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Oct 30, 2025 • Yahoo Finance
Earnings call transcript: Agios Pharm Q3 2025 beats revenue forecasts
Oct 30, 2025 • Investing.com
Agios Pharmaceuticals’ AG-236 Study: A Potential Game-Changer in Drug Development
Oct 29, 2025 • The Globe and Mail
Agios Pharmaceuticals Ensures Continued Access to Mitapivat in New Study
Oct 28, 2025 • The Globe and Mail
Agios Pharmaceuticals (AGIO): Exploring Valuation Following Positive EU Opinion for PYRUKYND Approval
Oct 27, 2025 • Sahm
Agios Pharmaceuticals (AGIO): Exploring Valuation Following Positive EU Opinion for PYRUKYND Approval
Oct 27, 2025 • simplywall.st
Agios Pharmaceuticals’ AG-181 Study: A Potential Game-Changer in Drug Development
Oct 27, 2025 • TipRanks
EMA Committee’s Positive Opinion on PYRUKYND Might Change The Case For Investing In Agios Pharmaceuticals (AGIO)
Oct 25, 2025 • simplywall.st
EMA Committee’s Positive Opinion on PYRUKYND Might Change The Case For Investing In Agios Pharmaceuticals (AGIO)
Oct 25, 2025 • Sahm
H.C. Wainwright reiterates Buy rating on Agios Pharma stock amid positive EMA opinion
Oct 20, 2025 • Investing.com
A Look at Agios Pharmaceuticals’s Valuation After Key EMA Milestone for PYRUKYND Expansion
Oct 19, 2025 • Sahm
Evaluating Agios Pharmaceuticals After 16% Rally and Positive Early Data on Mitapivat in Sickle Cell Disease
Oct 18, 2025 • Yahoo Finance
How Positive CHMP Opinion and European Deal for PYRUKYND May Impact Agios Pharmaceuticals (AGIO) Investors
Oct 17, 2025 • Sahm
European regulators back Agios’ thalassemia treatment
Oct 17, 2025 • Investing.com
Agios Pharmaceuticals Receives Positive CHMP Opinion for PYRUKYND® Indication in Thalassemia Treatment
Oct 17, 2025 • Quiver Quantitative
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia
Oct 17, 2025 • Yahoo Finance
Agios Pharmaceuticals Getting Closer To Key Technical Benchmark
Oct 16, 2025 • Investor's Business Daily
Agios Pharmaceuticals to Host Conference Call for Q3 2025 Financial Results and Business Highlights
Oct 16, 2025 • Quiver Quantitative
Earnings call transcript: Agios Pharm Q2 2025 sees 45% revenue jump
Oct 14, 2025 • Investing.com
Analyzing recovery setups for Agios Pharmaceuticals Inc. investors - July 2025 Recap & AI Based Trade Execution Alerts
Oct 10, 2025 • newser.com
Zacks Research Issues Pessimistic Outlook for AGIO Earnings
Oct 10, 2025 • MarketBeat
Agios Pharmaceuticals' (AGIO) Hold (C-) Rating Reiterated at Weiss Ratings
Oct 8, 2025 • MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Cut to "Strong Sell" at Zacks Research
Oct 8, 2025 • MarketBeat
Agios Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics
Oct 8, 2025 • Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Oct 3, 2025 • cnhinews.com
Agios Pharmaceuticals Hits Day High with 9.64% Surge in Stock Price
Sep 30, 2025 • Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Sep 28, 2025 • PR Newswire
Voya Investment Management LLC Sells 17,760 Shares of Agios Pharmaceuticals, Inc. $AGIO
Sep 28, 2025 • MarketBeat
Strs Ohio Purchases New Shares in Agios Pharmaceuticals, Inc. $AGIO
Sep 25, 2025 • MarketBeat
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Sep 18, 2025 • PR Newswire
Agios Pharmaceuticals’ SWOT analysis: FDA delay impacts stock outlook
Sep 17, 2025 • Investing.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.00 Average PT from Analysts
Sep 17, 2025 • MarketBeat
Servier’s Voranigo backed by MHRA for astrocytoma or oligodendroglioma
Sep 16, 2025 • Pharma Letter
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm
Sep 15, 2025 • Business Wire
Atavistik Bio Appoints Susan Pandya, M.D., as Chief Medical Officer
Sep 15, 2025 • citybiz
Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer
Sep 15, 2025 • Atavistik Bio, Inc.
Atavistik Bio Appoints Susan Pandya as Chief Medical Officer
Sep 15, 2025 • citybiz
Agios Pharmaceuticals (AGIO): Valuation Insights Following FDA Extension of PYRUKYND Review Timeline
Sep 13, 2025 • simplywall.st
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Sep 13, 2025 • Morningstar.com
Capsida Reports Patient Death in Gene Therapy Trial
Sep 11, 2025 • BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
Sep 10, 2025 • Pomerantz LLP
Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive (NASDAQ:AGIO)
Sep 8, 2025 • Seeking Alpha
FDA Review Delay for PYRUKYND Might Change the Case for Investing in Agios Pharmaceuticals (AGIO)
Sep 8, 2025 • Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Sep 8, 2025 • PR Newswire